"id","studyRationale","uuid:ID","studyTitle","studyVersion","studyAcronym"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","25711687-0b79-428b-9399-180aa33d98fe","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","2","H2Q-MC-LZZT"
